The present proposal aims at capitalizing on these preliminary data and on our analytical know- how to join forces with computer scientists of the Swiss Data Science Center and with clinicians involved in cancer care in order to mature TE-targeting technology (TETT) into a pillar of personalized health and individualized management in the field of oncology.
Transposable elements (TEs) may contribute up to 80% of the human genome. Long considered as junk DNA, this so-called endovirome is now recognized as an essential motor of evolution. Over the last few years, we developed a leading expertise in the extraction and analysis of TE-derived information (TEDI). This allowed us to uncover that tens of thousands of TE loci are expressed in all examined human tissues, from embryonic stem cells to terminally differentiated neurons, that they are under exquisite control by a large family of developmental stage- and tissue-restricted modulators, and that they exert profound regulatory influences on the expression of cellular genes. We further determined that the sum of TE-derived transcripts, which we coined the transposcriptome, provides a high-density barcode for cell identity, differentiation level and activation status, with a far greater precision that its gene-based counterpart.
Turning to cancer, we obtained data indicating that TEDI can be an unmatched source of biomarkers and specific neo-antigens for targeting by immunotherapy.